Your browser doesn't support javascript.
loading
Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys.
Yeh, Wendy W; Rahman, Ishita; Hraber, Peter; Coffey, Rory T; Nevidomskyte, Daiva; Giri, Ayush; Asmal, Mohammed; Miljkovic, Svetlana; Daniels, Marcus; Whitney, James B; Keele, Brandon F; Hahn, Beatrice H; Korber, Bette T; Shaw, George M; Seaman, Michael S; Letvin, Norman L.
Affiliation
  • Yeh WW; Division of Viral Pathogenesis, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
J Virol ; 84(12): 6018-32, 2010 Jun.
Article in En | MEDLINE | ID: mdl-20357097
ABSTRACT
While the simian immunodeficiency virus (SIV)-infected rhesus monkey is an important animal model for human immunodeficiency virus type 1 (HIV-1) infection of humans, much remains to be learned about the evolution of the humoral immune response in this model. In HIV-1 infection, autologous neutralizing antibodies emerge 2 to 3 months after infection. However, the ontogeny of the SIV-specific neutralizing antibody response in mucosally infected animals has not been defined. We characterized the kinetics of the autologous neutralizing antibody response to the transmitted/founder SIVmac251 using a pseudovirion-based TZM-bl cell assay and monitored env sequence evolution using single-genome amplification in four rhesus animals that were infected via intrarectal inoculations. We show that the SIVmac251 founder viruses induced neutralizing antibodies at 5 to 8 months after infection. Despite their slow emergence and low titers, these neutralizing antibodies selected for escape mutants that harbored substitutions and deletions in variable region 1 (V1), V2, and V4 of Env. The neutralizing antibody response was initially focused on V4 at 5 to 8 months after infection and then targeted V1/V2 and V4 by 16 months. These findings reveal a striking delay in the development of neutralizing antibodies in SIVmac-infected animals, thus raising questions concerning the suitability of SIVmac251 as a challenge strain to screen AIDS vaccines that elicit neutralizing antibodies as a means to prevent virus acquisition. They also illustrate the capacity of the SIVmac quasispecies to modify antigenic determinants in response to very modest titers of neutralizing antibodies.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / Simian Acquired Immunodeficiency Syndrome / Simian Immunodeficiency Virus / Antibodies, Neutralizing / Antibodies, Viral Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: J Virol Year: 2010 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / Simian Acquired Immunodeficiency Syndrome / Simian Immunodeficiency Virus / Antibodies, Neutralizing / Antibodies, Viral Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: J Virol Year: 2010 Document type: Article Affiliation country: United States